newest glp 1 agonist Market Overview: GLP-1 Agonists and the Obesity Market | Blog Frontiers | GLP-1 Receptor Agonists:

Race and ethnicity Relatively few RCTs have conducted formal subgroup analyses by race or ethnicity, and available data are limited by underrepresentation of non-White participants

These medications may interfere with oral contraceptives

doi: 10.1517/17460441.2014.942638 67 HorowitzMRaynerCKJonesKL

[DOI] [PMC free article] [PubMed] [Google Scholar] 28

Percentage shares and splits were determined based on the revenue contributed to each of the segments

A notable development is the launch of Wegovy by Novo Nordisk A/S in March 2024, the first once-weekly GLP-1 therapy designed to manage weight effectively, showcasing a safe and convenient approach for patients